Hemocompatibility of anticoagulant biomaterials

doi:10.3969/j.issn.2095-4344.2013.08.028

Abstract

Abstract:

BACKGROUND: Experts believe that the improvement of hemocompatibility of the anticoagulant biomaterials can significantly improve the anticoagulant properties of the anticoagulant biomaterials.
OBJECTIVE: To evaluate the hemocompatibility of the polyester-based and titanium-based anticoagulant biomaterials.
METHODS: The effect of polyester-based and titanium-based anticoagulant biomaterials on the level of red blood cells, platelets, albumin, fibrin and coagulation factors was explored through searching the relative literatures. The anticoagulant properties of the polyester-based and titanium-based anticoagulant biomaterials were analyzed through the hemolysis test, dynamic blood coagulation test, platelet adhesion test, serum protein adsorption experiment recalcification test and lactate dehydrogenase releasing test, thus the hemocompatibility of the polyester-based and titanium-based anticoagulant biomaterials was evaluated.
RESULTS AND CONCLUSION: The hemolysis rate of polyester-based and titanium-based anticoagulant biomaterials was significantly decreased, and the polyester-based and titanium-based anticoagulant biomaterials have less platelet adhesion and increased adsorption amount of albumin, and the fibrinogen adsorption was significantly reduced, the recalcification time and clotting time was significantly prolonged. The polyester-based and titanium-based anticoagulant biomaterials show a higher anti-clotting property, which are ideal anticoagulant biomaterials.

Key words: biomaterials, academic discussion of biomaterials, anticoagulant, hemocompatibility, platelets, fibrin, albumin, polyurethane, titanium, titanyl film, hemolysis rate, recalcification time

CLC Number:

R318

Zhang Ming-hua, Zheng Hai-yan. Hemocompatibility of anticoagulant biomaterials[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(8): 1505-1512.

Figures/Tables 5

References

[1] Macocinschi D, Filip D, Vlad S, et al. Segmented biopolyurethanes for medical applications. J Mater Sci Mater Med. 2009;20(8):1659-1668.

[2] Kütting M, Roggenkamp J, Urban U, et al. Polyurethane heart valves: past, present and future. Expert Rev Med Devices. 2011;8(2):227-233.

[3] Gastaldello K, Melot C, Kahn RJ, et al. Comparison of cellulose diacetate and polysulfone membranes in the outcome of acute renal failure. A prospective randomized study. Nephrol Dial Transplant. 2000;15(2):224-230.

[4] Suzuki Y, Daitoku K, Minakawa M, et al. Poly-2-methoxyethylacrylate-coated bypass circuits reduce activation of coagulation system and inflammatory response in congenital cardiac surgery. J Artif Organs. 2008;11(3): 111-116.

[5] Kwok SC, Yang P, Wang J, et al. Hemocompatibility of nitrogen-doped, hydrogen-free diamond-like carbon prepared by nitrogen plasma immersion ion implantation-deposition. J Biomed Mater Res A. 2004;70(1):107-114.

[6] Santerre JP, Woodhouse K, Laroche G, et al. Understanding the biodegradation of polyurethanes: from classical implants to tissue engineering materials. Biomaterials. 2005;26(35): 7457-7470.

[7] Losi P, Lombardi S, Briganti E, et al. Luminal surface microgeometry affects platelet adhesion in small-diameter synthetic grafts. Biomaterials. 2004;25(18):4447-4455.

[8] 沈健.生物医用高分子材料的研制及其基础研究[D].江苏:南京理工大学,2004:1-396.

[9] 马银陈,周宁琳,陈亚红,等.新型抗凝血纳米复合材料的制备及其性能研究[J].功能材料,2007,38(10):1713-1716.

[10] 程莉萍,孙树东,乐以伦,等.血液净化膜材和抗凝剂对凝血过程中接触活化的影响[J].四川大学学报:医学版,2005,36(3):411-414.

[11] 中国知网.中国学术期刊总库[DB/OL].2012-11-18. https://www.cnki.net.

[12] 任振俶.羧基化壳聚糖改性聚氨酯的制备和表征[D].辽宁:大连理工大学,2012:1-67.

[13] 贺春丽.不同类型亲水结构表面修饰聚氨酯的合成及其生物相容性研究[D].江苏:南京师范大学,2011:1-84.

[14] 吕博.抗凝血Ti-O薄膜的电化学行为研究[D].四川:西南交通大学, 2010:1-52.

[15] 杨忠海.氢等离子体改性Ti-O薄膜的血液相容性研究[D].四川:西南交通大学,2009:1-87.

[16] 谢赞.表面接枝胆甾相液晶改善PU的抗凝血性能研究[D].广东:暨南大学,2007:1-59.

[17] 董艳霞.钛表面改性及其血液相容性研究[D].陕西:陕西师范大学, 2007:1-68.

[18] 宋杰,吴熹,黄楠,等.纤维蛋白原与吸附白蛋白、肝素的新型血管支架材料氧化钛的血液相容性[J].生物医学工程学杂志,2007, 24(5):1097-1101.

[19] 周红芳.离子注入钛氧薄膜的血液相容性研究[D].四川:西南交通大学,2006:1-66.

[20] 霍丹群.肝素化高分子液晶/聚醚氨酯生物材料的研究[D].重庆:重庆大学,2004:1-157.

[21] 郑书家.抗凝血生物材料的血液相容性研究[D].重庆:重庆大学,2004:1-62.

[22] Lelah M, Pierce JA, Lambrecht LK, et al. Polyether-urethane ionomers:surface property/ex vivo blood compatibility relationships. J Colloid Interface Sci. 1985;104(2):422-439.

[23] Ito Y, Sisido M, Imanishi Y. Synthesis and antithrombogenicity of anionic polyurethanes and heparin-bound polyurethanes. J Biomed Mater Res. 1986;20(8):1157-1177.

[24] Goosen MF, Sefon MV. Properties of a heparin-poly(vinyl alcohol) hydrogelcoating. J Biomed Mater Res. 1993;17: 359-361.

[25] Bélanger MC, Marois Y, Roy R, et al. Selection of a polyurethane membrane for the manufacture of ventricles for a totally implantable artificial heart: blood compatibility and biocompatibility studies. Artif Organs. 2000;24(11):879-888.

[26] 王小梅.肝素化壳聚糖/大豆蛋白质复合材料的制备及其抗凝血功能研究[D].湖北:武汉大学,2011:1-149.

[27] 俞洪飞.医用涤纶材料表面磷酸胆碱仿生改性及其抗凝血性能研究[D].四川:西南交通大学,2011:1-63.

[28] 张麟,陈弟虎,于凤梅,等.氧化镧掺杂非晶碳薄膜的血液相容性[J].生物医学工程研究,2009,28(2):96-99.

[29] 王亮.改善有机硅（PDMS）弹性体表面血液相容性的研究[D].湖北:武汉理工大学,2008:1-60.

[30] 单婧.聚硅氧烷液晶的合成及其聚合物共混材料的结构与血液相容性研究[D].广东:暨南大学,2008:1-90.

[31] 马丹.医用无镍不锈钢的血液相容性的研究[D].辽宁:沈阳工业大学,2007:1-66.

[32] 陈亚红.聚合物/蒙脱土纳米抗凝血复合材料的研究[D].江苏:南京师范大学,2007:1-75.

[33] 陈亚红,周宁琳,孟娜,等.改性氧化石墨/聚合物的制备及其体外抗凝血性能的评价[J].功能材料,2007,38(3):438-440.

[34] 马晓星.低温等离子体表面改性PET材料及其抗凝血性能的研究[D].北京:北京化工大学,2007:1-77.

[35] 牟善松,屠美,汤顺清,等.羟基磷灰石对硅橡胶复合材料抗凝血性能的影响(英文)[J].材料科学与工程学报,2003,21(2):162-164.

[36] Zhu Q, Wang Y, Zhou M, et al. Preparation of anionic polyurethane nanoparticles and blood compatible behaviors. J Nanosci Nanotechnol. 2012;12(5):4051-4056.

[37] Nie S, Xue J, Lu Y, et al. Improved blood compatibility of polyethersulfone membrane with a hydrophilic and anionic surface. Colloids Surf B Biointerfaces. 2012;100:116-125.

[38] Joung YK, You SS, Park KM, et al. In situ forming, metal-adhesive heparin hydrogel surfaces for blood-compatible coating. Colloids Surf B Biointerfaces. 2012;99:102-107.

[39] You I, Kang SM, Byun Y, et al. Enhancement of blood compatibility of poly(urethane) substrates by mussel-inspired adhesive heparin coating. Bioconjug Chem. 2011;22(7):1264-1269.

[40] Weng Y, Tan H, Huang N, et al. Study on immobilization of heparin on surface of Ti-O films and its antithrombogenicity. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2011;28(1):86-89.

[41] Li G, Yang P, Qin W, et al. The effect of coimmobilizing heparin and fibronectin on titanium on hemocompatibility and endothelialization. Biomaterials. 2011;32(21):4691-4703.

[42] Chang Y, Chang WJ, Shih YJ, et al. Zwitterionic sulfobetaine-grafted poly(vinylidene fluoride) membrane with highly effective blood compatibility via atmospheric plasma-induced surface copolymerization. ACS Appl Mater Interfaces. 2011;3(4):1228-1237.

[43] Li G, Yang P, Liao Y, et al. Tailoring of the titanium surface by immobilization of heparin/fibronectin complexes for improving bloodcompatibility and endothelialization: an in vitro study. Biomacromolecules. 2011;12(4):1155-1168.

[44] Gericke M, Doliška A, Stana J, et al. Semi-synthetic polysaccharide sulfates as anticoagulant coatings for PET, 1--cellulose sulfate. Macromol Biosci. 2011;11(4):549-556.

[45] Huang XJ, Guduru D, Xu ZK, et al. Blood compatibility and permeability of heparin-modified polysulfone as potential membrane for simultaneous hemodialysis and LDL removal. Macromol Biosci. 2011;11(1):131-140.

[46] Wagner WR, Johnson PC, Thompson KA, et al. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. Ann Thorac Surg. 1994;58(3):734-740; discussion 741.

[47] Bozdayi M, Borowiec J, Nilsson L, et al. Effects of heparin coating of cardiopulmonary bypass circuits on in vitro oxygen free radical production during coronary bypass surgery. Artif Organs. 1996;20(9):1008-1016.

[48] Høgevold HE, Moen O, Fosse E, et al. Effects of heparin coating on the expression of CD11b, CD11c and CD62L by leucocytes in extracorporeal circulation in vitro. Perfusion. 1997;12(1):9-20.

[49] Moen O, Fosse E, Brockmeier V, et al. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems. Ann Thorac Surg. 1995;60(5):1317-1323.